5-Hydroxy-2,3-dihydro-1,4-phthalazindion | 7600-08-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 5-Hydroxy-2,3-dihydro-1,4-phthalazindion
• 英文别名: 5-Hydroxy-2,3-dihydrophthalazine-1,4-dione
• CAS: 7600-08-0
• 化学式: C₈H₆N₂O₃
• mdl: MFCD02929853
• 分子量: 178.147
• InChiKey: ZBUBTIDFWFQVLJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  78.4
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-Hydroxy-2,3-dihydro-1,4-phthalazindion 、 三氯化铁 在 氢氧化钾 作用下， 以 水 为溶剂， 生成
  参考文献：
  名称：

  Kalinichenko, I. E.; Barovskii, V. A.; Pilipenko, A. T., Journal of General Chemistry of the USSR, 1983, vol. 53, p. 1603 - 1608

  摘要：

  DOI：
• 作为产物：
  描述：

  邻苯二甲酰肼 在 双氧水 、 碳酸氢钠 、 sodium chloride 、 copper dichloride 作用下， 以 水 为溶剂， 生成 5-Hydroxy-2,3-dihydro-1,4-phthalazindion
  参考文献：
  名称：

  Fenton-like copper redox chemistry revisited: Hydrogen peroxide and superoxide mediation of copper-catalyzed oxidant production

  摘要：

  Copper toxicity has been attributed to its potential as a catalyst for oxidative damage to tissues through redox cycling between Cu(I) and Cu(II), particularly in the presence of H2O2, a by-product of oxygen metabolism. In this study, the reactions of nanomolar concentrations of Cu(I) and Cu(II) with H2O2 have been investigated in 2.0 mM NaHCO3 and 0.7 M NaCl at pH 8.0. Measurements of both the formation of the hydroxylated phthalhydrazide chemiluminescent product and the degradation of formate in the absence and presence of compounds with well-known reactivity with HO center dot indicated that the reaction between Cu(I) and H2O2 did not result in the production of HO center dot but involved the formation of a higher oxidation state of copper, Cu(III). The Cu(III) so-formed reacts with the substrates that were present at much slower rates compared to those of HO center dot. The rate of formation of HO center dot from the dissociation of Cu(III) was extremely slow at pH 8.0 with the result that HO center dot is not an important oxidant in this system. The rapid rate of reaction of Cu(III) with Cu(I) contributes significantly to the redox cycle of copper and the associated oxidizing capacity of the Cu(I)/Cu(II)/H2O2/O-2 system with exogenous input of H2O2 and O-2(center dot-) exhibiting the ability to mediate ongoing copper-catalyzed production of the powerful oxidant, Cu(III). (C) 2013 Elsevier Inc. All rights reserved.

  DOI：

  10.1016/j.jcat.2013.01.025

文献信息

• Enzyme-catalyzed chemiluminescence from hydroxyaryl cyclic
  申请人：Lumigen, Inc.

  公开号：US05552298A1

  公开（公告）日：1996-09-03

  An assay method, compositions and test kits using a hydroxyaryl cyclic diacylhydrazide is described. A hydrogen peroxide and peroxidase enzyme. The preferred compositions incorporate enhancer compounds and a chelating agent which suppresses light production prior to addition of a peroxidase enzyme. The assay method can test for a peroxidase enzyme, a peroxide or can be used in immunoassays and probe assays.

  本文描述了使用羟基芳基环状二酰肼的测定方法、组成物和试剂盒。使用了过氧化氢和过氧化酶酶。首选组成物包括增强剂化合物和螯合剂，可在加入过氧化酶酶之前抑制发光。该测定方法可用于检测过氧化酶酶、过氧化物或用于免疫测定和探针测定。
• Azocompounds for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
  申请人：UNIVERSITY OF PITTSBURGH

  公开号：EP1110945A2

  公开（公告）日：2001-06-27

  Amyloid binding compounds which are derivatives of Chrysamine G, pharmaceutical compositions containing, and methods using such compounds to identify Alzheimer's brain in vivo and to diagnose other pathological conditions characterized by amyloidosis, such as Down's Syndrome are described. Pharmaceutical compositions containing Chrysamine G and derivatives thereof and methods using such compositions to prevent cell degeneration and amyloid-induced toxicity in amyloidosis associated conditions are also described. Methods using Chrysamine G derivatives to stain or detect amyloid deposits in biopsy or post-mortem tissue are also described. Methods using Chrysamine G derivatives to quantify amyloid deposits in homogenates of biopsy and post-mortem tissue are also described.

  本文描述了作为金黄胺 G 衍生物的淀粉样蛋白结合化合物、含有此类化合物的药物组合物以及使用此类化合物鉴定体内阿尔茨海默氏症大脑和诊断以淀粉样变性为特征的其他病理状况（如唐氏综合症）的方法。此外，还描述了含有金黄胺 G 及其衍生物的药物组合物，以及使用此类组合物在淀粉样变性相关病症中防止细胞变性和淀粉样诱导毒性的方法。还介绍了使用金黄胺 G 衍生物染色或检测活检或死后组织中淀粉样沉积物的方法。还介绍了使用金黄胺 G 衍生物量化活检组织和死后组织匀浆中淀粉样蛋白沉积的方法。
• Solution phase homogeneous assays
  申请人：Beckman Coulter, Inc.

  公开号：US10036708B2

  公开（公告）日：2018-07-31

  Methods, reagents, kits and systems are disclosed for determining an analyte in a sample suspected of containing the analyte where all reagents are soluble in aqueous solution. One assay method includes treating a sample suspected of containing the analyte under conditions such that if the analyte is present, an activator is brought into reactive configuration with a chemiluminescent compound to activates it. The sample is also treated with an agent to reduce signal not related to analyte. Finally, the sample is treated with a trigger solution thereby producing light from the activated chemiluminescent compound. No reagents are associated with a surface or other solid phase.

  本发明公开了用于测定疑似含有分析物的样品中分析物的方法、试剂、试剂盒和系统，其中所有试剂均可溶于水溶液。一种检测方法包括处理疑似含有被分析物的样品，如果样品中存在被分析物，则将活化剂与化学发光化合物反应配置，使其活化。还用一种药剂处理样品，以减少与分析物无关的信号。最后，用触发溶液处理样品，从而使活化的化学发光化合物发光。试剂与表面或其他固相无关。
• Treatment of proliferative disorders with a chemiluminescent agent
  申请人：Semorex Technologies Ltd.

  公开号：US10092565B2

  公开（公告）日：2018-10-09

  Methods employing chemiluminescent agents as therapeutically active agents in the treatment of proliferative disorders are disclosed. The chemiluminescent agents are used in the disclosed method without a therapeutically effective amount of a photosensitizer. Novel chemiluminescent agents having the general formula: are also disclosed, wherein X, Y, Z, R3 and R5-R9 are as defined herein.

  本发明公开了使用化学发光制剂作为治疗活性制剂治疗增殖性疾病的方法。 在所公开的方法中使用的化学发光剂不含治疗有效量的光敏剂。 还公开了具有通式：的新型化学发光制剂，其中 X、Y、Z、R3 和 R5-R9 如本文所定义。
• Specific binding chemiluminescent assay
  申请人：3M INNOVATIVE PROPERTIES COMPANY

  公开号：US11320424B2

  公开（公告）日：2022-05-03

  Method of assaying for an analyte in a sample, and kits for performing the assay.

  化验样品中分析物的方法，以及进行化验的试剂盒。